Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (12 ops.)
Latest filing published 14 Sept 2026 for Amylyx Pharmaceuticals, Inc., €220k. Read the official filing
Filing timeline
BuySaleCamille L. Bedrosian
Insider track record
Disclosed buys
0
Disclosed sells
12
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Camille L. Bedrosian: trading record in brief
This profile gathers the share dealings of Camille L. Bedrosian across 4 companies, led by Amylyx Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. Between 6 May 2021 and 10 September 2026, the trades on record add up to 27 filings.
Sales make up the whole of the open-market record (12 sales, €1.0M). The rest of the record consists of 10 share grants and 3 option exercises. So far in 2026, the count stands at no purchases and 3 sales.
The latest filing, published on 14 September 2026, reports an open-market sale of €59k in Amylyx Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Camille L. Bedrosian
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations27 total
7,947 shares@ US$32.2139Common StockSEC:0001193125-26-390510:0
2,081 shares@ US$33.0919Common StockSEC:0001193125-26-390510:1
5,925 shares@ US$85.000.0056% mcap26.7% of flowCommon StockSEC:0001628280-26-059900:1
16,300 shares@ US$85.000.015% mcap73.3% of flowCommon StockSEC:0001628280-26-059900:0
22,807 shares0Common StockSEC:0001193125-26-359676:0
5,925 sharesCommon StockSEC:0001628280-26-044712:0
95,990 shares0Common StockSEC:0001193125-26-098436:0
6,461 shares@ US$14.580619.4% of flowCommon StockSEC:0001193125-26-091440:0
6,580 shares@ US$14.349324.5% of flowCommon StockSEC:0001193125-25-306818:0
12,039 shares@ US$14.579159.7% of flowCommon StockSEC:0001193125-25-228339:0
4,000 sharesCommon StockSEC:0001104659-25-061711:0
6,900 shares0Common StockSEC:0000950170-25-086265:0
12,425 shares@ US$3.467439.4% of flowCommon StockSEC:0000950170-25-049567:0
68,420 shares0Common StockSEC:0000950170-25-036712:0
5,421 shares@ US$5.535428.1% of flowCommon StockSEC:0000950170-24-132885:0
11,442 shares@ US$3.195232.5% of flowCommon StockSEC:0000950170-24-111809:0
3,000 sharesCommon StockSEC:0001104659-24-074767:0
3,400 shares0Common StockSEC:0000950170-24-071923:0
96,910 shares0Common StockSEC:0000950170-24-045693:0
58,333 shares0Common StockSEC:0000950170-23-066796:0
6,000 shares0Common StockSEC:0001209191-23-038818:0
2,663 shares0Common StockSEC:0001209191-23-016053:0
2,821 shares@ US$66.6237.9% of flowCommon StockSEC:0001209191-22-015802:0
1,657 shares@ US$66.3022.3% of flowCommon StockSEC:0001209191-22-005838:0
359 shares@ US$81.145.7% of flowCommon StockSEC:0001209191-21-060765:0
25 of 27 declarations
